EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CMV management of patients with leukopenia after CMV high-risk kidney transplantation

Amina Abu-Omar, Janine Mihm, Saskia Bronder, Tina Schmidt, Martina Sester, Urban Sester

Transplant Immunology · 2025

DOI: 10.1016/j.trim.2025.102188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2025. Verfasst von Amina Abu-Omar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany; Department of Internal Medicine IV, Saarland University, Ho…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Leukopenia, Kidney Transplantation, Cytomegalovirus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Saarland University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For CMV high-risk constellations, guidelines recommend 3-6 months of prophylaxis with valganciclovir (VGCV). Management in preventing CMV primary infection in patients developing VGCV-associated leukopenia remains challenging. METHODS: We retrospectively analyzed the development of leukopenia during VGCV prophylaxis in 57 seronegative kidney recipients of a CMV-seropositive donor between 2008 and 2021. We analyzed CMV risk and development of CMV-specific T cells in the first post-transplant year depending on leukopenia during VGCV prophylaxis and management with CMV-IVIg. RESULTS: Leukopenia developed in 19/57 patients, with a significant difference in leukocyte counts occurring after 10 weeks of VGCV prophylaxis compared to patients without leukopenia (p = 0.0003). VGCV discontinuation led to leukocyte reconstitution, which tended to be faster in patients receiving additional prophylaxis with CMV-IVIg after VGCV discontinuation (n = 11, p = 0.083). In the first post-transplant year, patients with leukopenia had no higher risk for severe CMV events. Interestingly, patients receiving CMV-IVIg prophylaxis showed a significantly lower peak CMV-load during primary infection (p = 0.040), with no difference in CMV-specific T-cell levels compared to patients without leukopenia or patients with additional CMV-IVIg prophylaxis (p = 0.972). Patients developing adequate CMV-specific T-cell responses less frequently underwent CMV reactivation 50 days following primary infection. CONCLUSION: Leukopenia developed late during VGCV prophylaxis and did not result in an increased risk for CMV primary infections or severe disease. Leukopenic patients receiving CMV-IVIg tended to have a faster leukocyte reconstitution and had lower peak DNAemia, which did not adversely affect CMV-specific T-cell induction. CMV-IVIg may therefore be considered as an alternative prophylactic strategy in patients with VGCV-associated leukopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsLeukopeniaKidney TransplantationCytomegalovirusAntiviral AgentsValganciclovirImmunoglobulins, IntravenousT-LymphocytesHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAged

Stichwörter der Autor:innen

CMV immunoglobulinsCytomegalovirusLeukopeniaT cellsValganciclovir

Substanzen

Antiviral AgentsValganciclovirImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany; Department of Internal Medicine IV, Saarland University, Homburg, Germany.
  • SHG Kliniken, Völklingen, Germany.
  • Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
  • Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany; Center for Gender-specific Biology and Medicine (CGBM), Saarland University, Homburg, Germany. Electronic address: martina.sester…

Förderung

  • Saarland University

Zitieren

APA

Abu-Omar, A., Mihm, J., Bronder, S., Schmidt, T., Sester, M., & Sester, U. (2025). CMV management of patients with leukopenia after CMV high-risk kidney transplantation. Transplant Immunology. https://doi.org/10.1016/j.trim.2025.102188

Vancouver

Abu-Omar A, Mihm J, Bronder S, Schmidt T, Sester M, Sester U. CMV management of patients with leukopenia after CMV high-risk kidney transplantation. Transplant Immunology. 2025. doi:10.1016/j.trim.2025.102188

BibTeX
@article{AbuOmar2025,
  author = {Abu-Omar, Amina and Mihm, Janine and Bronder, Saskia and Schmidt, Tina and Sester, Martina and Sester, Urban},
  title = {CMV management of patients with leukopenia after CMV high-risk kidney transplantation},
  journal = {Transplant Immunology},
  year = {2025},
  doi = {10.1016/j.trim.2025.102188}
}
Kostenlos starten →